The RAF/MEK/ERK (MAP Kinase) pathway is the index oncogenic signaling towards which many 3 compounds have been developed and tested for the treatment of KRAS-driven cancers, including 4 pancreatic ductal adenocarcinoma (PDA). Here, we explored the immunological changes induced 5 by targeted MEK1/2 inhibition (MEKi) using trametinib in preclinical mouse models of PDA. We 6 evaluated the dynamic changes in the immune contexture of mouse PDA upon MEKi using a 7 multidimensional approach (mRNA analyses, flow cytometry, and immunophenotyping). Effect of 8 MEKi on the viability and metabolism of macrophages was investigated in vitro. We showed that 9 transcriptional signatures of MAP Kinase activation are enriched in aggressive human PDA 10 subtype (squamous/basal-like/quasimesenchymal), while short term MEKi treatment in mouse 11 PDA induced subtype switching. Integrative mRNA expression and immunophenotypic analyses 12 showed that MEKi reshapes the immune landscape of PDA by depleting rather than 13 reprogramming macrophages, while augmenting infiltration by neutrophils. Depletion of 14 macrophages is observed early in the course of in vivo treatment and is at least partially due to 15 their higher sensitivity to MEKi. Tumor-associated macrophages were consistently reported to 16 interfere with gemcitabine uptake by PDA cells. Here, our in vivo studies show a superior 17 antitumor activity upon combination of MEKi and gemcitabine using a sequential rather than 18 simultaneous dosing protocol. Our results show that MEK inhibition induces a dramatic 19 remodeling of the tumor microenvironment of mouse PDA through depletion of macrophages, 20 which substantially improves the antitumor activity of gemcitabine.
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23 24 Table 6 .
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In line with gene expression data, one week of MEKi reduced the levels of 144 chemokines/cytokines (Ccl22, Ccl6, Ccl12, Ccl17) , which are also produced by TAM, 145 in protein lysates from whole tumor tissues ( Figure 3E and Figure S3F ). On the contrary, MEKi 146 increased levels of the matrix metalloproteases Mmp-3 and Mmp-9, the latter being mainly 147 produced by neutrophils ( Figure 3E and Figure S3F ). Multiparametric FACS analysis of tumors 148 treated for one week with MEKi confirmed a significant expansion of CD11b + Ly6G high Ly6C neg cells 149 (neutrophils) (Figure 3F ).
150
To validate the MEKi-induced changes in the infiltration of tumor by myeloid cells at tissue 151 level, we undertook immunophenotypic analysis of mice treated with MEKi. By staining both 152 vehicle-and MEKi-treated tissues for the macrophage marker F4/80 and Maf, a marker of anti-153 inflammatory macrophages (25-27), we found a reduction of total macrophages after one week 154 of MEKi treatment (Figure 4A ) and a more dramatic reduction of Maf + cells both after one and 155 two weeks of treatment (Figure 4B) . Immunostaining for Ly6G confirmed the increased infiltration 156 of neutrophils after one week of MEKi, while no further infiltration was observed at 2 weeks of mechanisms of T cell function and antigen presentation. There were no significant changes 161 induced by MEKi in immune signatures related to antigen presentation and activation of T cells 162 ( Figure S4A) . Since appropriate evaluation of signatures related to rare cell populations might be 163 difficult from bulk tissue expression analysis, we evaluated intratumoral infiltration of T cells 164 populations (CD8 + T cells and Foxp3 + cells) by immunophenotyping. We found increased 165 infiltration by CD8 + T cells following both 1 and 2 weeks of continuous MEKi treatment ( Figure   166 4D). Multiplex immunofluorescence revealed that while the total number of Foxp3 + cells (Treg) 167 were not affected (Figure 4E and Supplementary Figure 4B) , the treatment significantly 168 increased the fraction of Treg expressing PD1 (Figure 4E) . PD1 + CD8 + T cells were instead rare 169 in the tumor microenvironment of treated mice (Figure 4E and Supplementary 4C ).
170
We also tested whether MEKi was also able to affect the immunogenicity of FC1199 Next, we confirmed the MEKi-induced macrophage depletion in PDA tumor tissues in 181 independent isografts generated with the KPC derived cell line FC1245 and in CKP mice, a highly 182 aggressive spontaneous model of PDA (31) . The reduction in the number of Maf + macrophages 183 was evident after two days and persisted after two weeks of continuous MEKi treatment of 184 FC1245 tumor bearing mice (Figures S5A-D) . On the contrary, two days of MEKi were sufficient 185 to promote infiltration by neutrophils ( Figure S5E ).
186
To investigate effects of MEKi on macrophages on spontaneous PDA models, tumor-187 bearing CKP mice were treated for two days with 1mg/kg of MEKi. Consistent with the isografts 188 models, interrogation of the differential expression of 700 immune-related genes between 
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Reprogramming rather than depletion of macrophages has been recently suggested as a 207 successful strategy to increase sensitivity towards immunoncology (33, 34) . Therefore, we also 208 sought to assess if MEKi was able to induce reprogramming of macrophages towards anti-tumor 209 (pro-inflammatory) phenotypes. To this aim, we treated polarized macrophages with subIC50 210 concentrations of MEKi and evaluated expression of M1-like and M2-like markers by flow 211 cytometry to find that the treatment does not induce macrophages' reprogramming ( Figure 6A ).
212
In keeping with this, treatment of M2-polarized macrophages with MEKi did not revert completely 213 their metabolic features (Figure 6B-D) and when global gene expression of our treated isografts 214 was examined we did not observe increase of M1-driven signatures (Figure S6F ).
215
Overall, we showed that MEKi treatment induces changes of the immune contexture in 216 different murine PDA models with an early and persistent depletion of anti-inflammatory 217 macrophages.
219 220

MEKi-induced depletion of TAM increases response to Gemcitabine
221
Tumor-associated macrophages have been consistently reported to impair gemcitabine 222 efficacy in PDA by mechanisms involving drug uptake and metabolism (15, 16 
226
We thus questioned how MEKi treatment might interact with standard-of-care 227 gemcitabine-based chemotherapy given its ability of depleting the tumor microenvironment from 228 TAM. Gemcitabine is an anticancer nucleoside that works mainly through inhibition of DNA 229 synthesis (36). Notably, MEKi in vivo significantly reduced the number of cancer cells in the cell 230 cycle (Figure 1E ), suggesting that inhibition of MEK might reduce the number of cells targetable 231 by gemcitabine. To determine the optimal combination schedule, we evaluated the effect of MEKi 232 on S-phase progression following continuous drug treatment as well as after drug suspension in 233 vivo. 48 hours of continuous MEKi was sufficient to block EdU uptake, while S-phase reentry of 234 cancer cells was observed following 48 hours of MEKi discontinuation (Figure 6E ). This result 235 argued for alternate scheduling than concomitant treatment. Thus, we designed a survival study 236 based on one week of continuous MEKi treatment, in order to reduce the number of M2 237 macrophages, followed by two days of recovery before gemcitabine administration (Figure 6F ).
238
While gemcitabine (Gem) monotherapy had no effect on survival of tumor-bearing mice, MEKi 239 single agent treatment extended survival ( Figure 6G) . We observed a statistically significant 240 increase in overall survival for tumor-bearing mice receiving gemcitabine following 7 days on, 2 241 days off MEKi treatment compared to MEKi (p=0.014) and gemcitabine (p=0.001) as single 242 agents.
244
DISCUSSION
246
Therapeutic progress beyond more intensive chemotherapeutic regimen remains an 247 enigma in PDA with targeted and immune-based approaches failing so far. Recent sequencing 248 efforts have uncovered actionable segments of the PDA genome (37) and revealed the existence 249 of distinct phenotypes based on transcriptomic profiling of primary tumors (7, 11, 12) . While
250
showing distinct transcriptional signatures and different clinical behaviors (7, 11, 12) , PDA 251 subtypes all share the oncogenic activation of KRAS (7). Preclinical models have undoubtedly 252 shown that oncogenic KRAS drives the generation of a complex tumor microenvironment (TME),
253
where immunosuppressive myeloid cells represent the prominent cell type and T cells are rare 254 (29, 38) . This is consistent with the definition of PDA as an immunologically "cold" tumor (30). An 255 intense desmoplastic reaction with abundant macrophages and scant T cells is also observed in 256 humans (39). Recent work showed that a subset of PDA do exhibit moderate infiltration of T cells 257 (7, 40) and that T cell high tumors are usually associated with reduced myeloid cells content (29). 
278
Accordingly, we found that MEKi-induced TAM depletion was associated to increased infiltration 279 of CD8+ T cells. However, there was no indication of increased T cell reactivity or enhanced 280 antigen-presentation by DC cells from the mRNA analysis, further supporting the hypothesis of 281 an intrinsic DC/APC dysfunction in PDA tumor microenvironment (28). In keeping with this, in vitro 282 treatment of KPC derived cell lines with MEKi failed to increase expression of genes/proteins 283 involved in antigen presentation. A hallmark of the PDA squamous subtype is gene programs 284 associated with squamous differentiation and macrophage function (7) . A previous study has 285 shown that depletion of macrophages in KPC using a CSF1R inhibitor resulted in "subtype switch" 286 and reduced immunosuppressive microenvironment (14). In our model, we also observed a 287 "switch away" from the squamous/basal-like/quasimesenchymal subtype following MEKi 288 treatment. Taken together, our data shows that MEKi dramatically influences the TME in PDA by 289 causing early and persistent depletion of TAM. As tumor-associated macrophages have been 290 consistently reported to impair chemotherapy efficacy in PDA (15,16), we tested whether MEKi-291 induced macrophages depletion could sensitize to chemotherapy. TAMs have been shown to 292 specifically interfere with gemcitabine uptake by cancer cells through release of pyrimidines; 293 therefore, we used a sequence specific treatment with MEKi in combination with gemcitabine and 294 found superior antitumor activity compared to both gemcitabine and MEKi as single agents.
295
Our study demonstrates that MEK inhibition induces a profound remodeling of the TME in 296 preclinical models of PDA, which is associated to molecular subtype "switching". Notably, we 
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341
Mice 342 SIx-to 8-weeks old C57Bl/6J (B6J) mice were purchased from Charles River Laboratory.
343
All animal experiments regarding transplanted mice were conducted in accordance with 344 procedures approved by CIRSAL at University of Verona (approved project 655/2017-PR). 
366
Orthotopic tumor models and GEMM 367 6-to 8-weeks old B6J mice were transplanted with FC1199 or FC1245 cells (2.5x10 5 -368 5x10 5 ) resuspended in a 50% v/v solution of Matrigel in PBS. A volume of 50µL of solution was 369 injected into the pancreatic tail. For the definition of optimal trametinib dosage, FC1199 luc/Gfp 370 (5x10 5 cells/mouse) were orthotopically transplanted in B6J mice and, 10 days post 371 transplantation, mice were injected intraperitoneally with 200µL of a concentrated luciferin 372 solution (15mg/mL, PerkinElmer, Inc.) for IVIS imaging analysis (PerkinElmer). Mice were treated 373 daily by oral gavage for one week using two different concentrations of trametinib (0.3mg/kg and 374 1mg/kg). IVIS was performed at day -1 (the day before the beginning of treatments), then at day 375 6 (i.e., the day before necropsy). For therapeutic intervention studies, FC1199 (3.5x10 5 376 cells/mouse) were orthotopically transplanted in B6J mice. Upon detection of a palpable mass, 377 mice were subjected to high-contrast ultrasound imaging using the Vevo 2100 System with a 378 MS250, 13-24 MHz scanhead (Visual Sonics, Inc, Amsterdam, NL) and enrolled in treatment 379 studies according to the outlined treatment schedules. Mice were administered vehicle or 1mg/kg 380 MEKi every day by oral gavage unless otherwise indicated. Gemcitabine was administered i.p. at 381 a dose of 120mg/kg once a week. CKP mice were enrolled in treatment studies at age of 6 weeks 382 as previously described (31). Mice were treated with vehicle or trametinib (1mg/kg) daily, by oral 383 gavage, according to the reported treatment schedules.
385
Statistical Analysis and Data mining
386
For data mining and pancreatic cancer subtypes stratifications we used different gene 387 expression datasets. The two main datasets were the PACA-AU cohort of the ICGC consortium 388 and the TCGA-PAAD cohort of the TCGA consortium. The first was downloaded from the 389 supplementary material of the corresponding publication (7). This dataset contains normalized 
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Fourteen additional microarray and RNA-Seq datasets were downloaded and used for subtype 398 stratification. These datasets are listed in Supplementary Table 1 . Normalized expression values 399 were obtained with the GEOquery Bioconductor R package. For harmonization, all the datasets 400 were Z-scores standardized before subsequent analysis. The grouping of the samples in Bailey's,
401
Collisson's, and Moffitt's subtypes (7, 11, 12) was performed with the GSVA Bioconductor 402 package. The gene sets used for the stratification were retrieved from the original publications.
403
Unless indicated, all the p-values refers to Student's t-test.
405
Other conventional techniques are described in Supplementary Materials and Methods. 
413
GSVA stratified by Bailey (7), Moffitt (12), and Collisson (11) subtypes in the TCGA cohort.
414
Numeric p-values are from Student's t-test. See also Supplementary Figure 1 
459
See also Supplementary Table 5 and Supplementary Figure S3 . 
547
Indicated are the genes with log2FC expression ³ 2 and adjusted p<0.05. C Volcano plot of 548 differences in gene expression (NanoString platform) between vehicle-(n = 5) and two-weeks 
